Calculate Your Salary Ranking
Home > Joyant Pharmaceuticals Salary

Joyant Pharmaceuticals Salary
  • 49
  • 36
  • 38

Joyant Pharmaceuticals average salary is $77,320, median salary is $83,200 with a salary range from $65,000 to $83,200.
Joyant Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. Joyant Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 2 Joyant Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Chemist 65,000-83,200 Dallas, TX, 75201 2010 Joyant Pharmaceuticals Chemist Salaries (4)
Joyant Pharmaceuticals Dallas, TX Salaries
Research Associate 72,000-72,000 Dallas, TX, 75201 2010 Joyant Pharmaceuticals Research Associate Salaries (1)
Joyant Pharmaceuticals Dallas, TX Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent Joyant Pharmaceuticals Salaries (February 28, 2017)
Assistant Professor University of Oklahoma $42,860 Norman, OK, 73019 01/05/2015
General OMRON $65,998 Houston, TX, 77001 09/07/2015

Joyant Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Joyant Pharmaceuticals Information
  • Joyant Pharmaceuticals , Inc.
  • Industry: Other
  • City: Dallas, TX
  • Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Our core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of our company is on the development of unique chemical entities that operate by new cellular mechanisms. Our understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. We intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. Joyant was incorporated in November 2004 with the financial backing of Sanderling Ventures. Licensing